Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Overseas Profit Repatriation Supporters Include Schering-Plough, Lilly

This article was originally published in The Pink Sheet Daily

Executive Summary

Senate Minority Leader Daschle has yet to name conferees for the broader jobs bill, making it unlikely that any action on the legislation will be taken before the summer recess. Lilly has been the staunchest supporter of the repatriation provision for the pharma industry.

You may also be interested in...



“Repatriated” Funds Should Not Be Used For Rx Liability Costs – Congressman

House Ways & Means Health Subcommittee Ranking Member Stark (D-Calif.) urges the Treasury Department to prevent pharma companies such as Merck and Wyeth from using repatriated cash to cover legal expenses.

“Repatriated” Funds Should Not Be Used For Rx Liability Costs – Congressman

House Ways & Means Health Subcommittee Ranking Member Stark (D-Calif.) urges the Treasury Department to prevent pharma companies such as Merck and Wyeth from using repatriated cash to cover legal expenses.

Corporate "Tax Holiday" Nears President's Desk Following House Passage

The chamber approves a jobs bill containing a provision allowing U.S. companies to "repatriate" income claimed by overseas affiliates. The Senate is expected to consider the measure by Oct. 9.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel